Collaboration and Progress at EASL Liver Cancer Summit 2025

From the 20th until the 22nd of February, DiCE attended the EASL Liver Cancer Summit in Paris, France. We had several inspiring meetings with repre...

Read

DiCE Helps Shape New Liver Transplant Recommendations for Liver Cancer

Liver transplantation offers new hope for patients with liver cancer. DiCE has played a key role in shaping the most recent recommendations, which ...

Read

Advancing Liver Cancer Care: Highlights from the BCLC 2024 Meeting

On November 25th and 26th, DiCE virtually attended the Barcelone Clinic Liver Cancer (BCLC) annual conference, which was titled “Forging a Multid...

Read

Hepatocellular Carcinoma Prevention & Diagnosis: DiCE Publishes Project Results

DiCE’s mapping research project on HCC prevention and diagnosis in Europe reveals rising incidence and mortality rates. The results, published du...

Read

HCC Prevention and Diagnosis Mapping Survey

DiCE’s ongoing research project aimed at mapping the status quo in the prevention and diagnosis of hepatocellular carcinoma (HCC) across the ...

Read

DiCE is a Partner in HoloSurge: a Horizon Grant-Winning Project on Holographic Surgical Planning

DiCE is a partner in the HoloSurge project, which was awarded a Horizon Europe grant to improve surgical planning with hologram technology. One of ...

Read

Extending the Liver Cancer Index: HCC Prevention and Diagnosis Mapping

DiCE is launching its research project to map the status quo in preventing and treating hepatocellular carcinoma (HCC) across the EU. We will creat...

Read

COR2ED’s New Resources on Advanced HCC

COR2ED is an independent medical education company that develops impactful educational programmes within specific therapeutic areas. They have rece...

Read

ASCO GI Highlights – Positive Data in Earlier Stage HCC Results

The American Society for Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) was held in San Francisco, USA 18-20 January this year. At ...

Read

EU Commission Approval of Tibsovo® (Ivosidenib) in IDH1-mutated Cholangiocarcinoma

The European Commission approved the use of Tibsovo® (Ivosidenib) as monotherapy for the treatment of locally advanced or metastatic cholangiocarc...

Read

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.